AI assistant
CRISPR Therapeutics AG — Director's Dealing 2018
Dec 28, 2018
30936_dirs_2018-12-28_0beec4ce-28ad-4dab-b5ed-d6b245b6cf3c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-12-26
Reporting Person: Vertex Pharmaceuticals (Europe) Ltd (10% Owner)
Reporting Person: VERTEX PHARMACEUTICALS INC / MA (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-12-26 | Common Shares | P | 12737 | $24.8942 | Acquired | 5353479 | Direct |
| 2018-12-27 | Common Shares | P | 27461 | $24.9487 | Acquired | 5380940 | Direct |
Footnotes
F1: Shares are directly held by Vertex Pharmaceuticals (Europe) Limited ("Vertex Europe"). Vertex Europe is an indirect wholly owned subsidiary of Vertex Pharmaceuticals Inc. Vertex Pharmaceuticals Inc. may be deemed to beneficially own the shares owned directly by Vertex Europe.
F2: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.69 and $25.00.
F3: Represents the weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.85 and $25.00.